Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis.
Because human infections by Scedosporium prolificans are difficult to treat and show a very poor outcome, new therapeutic strategies are needed. Liposomal amphotericin B (LAMB) (40 mg/kg/day) increased significantly the mean survival time in immunosuppressed mice compared with a control group (22.6 vs. 8.8 days). Amphotericin B deoxycholate (1.5 mg/kg/day) and granulocyte colony-stimulating factor (G-CSF) (300 microg/kg/day) were ineffective. The combination of LAMB (40 mg/kg/day) and G-CSF (150 or 300 microg/kg/day) did not improve the results obtained with LAMB alone.
Ortoneda
Montserrat
M
Unitat de Microbiologia, Facultat de Medicina i Cències de la Salut, Universitat Rovira i Virgili, Reus, Spain.
Capilla
Javier
J
Pastor
F Javier
FJ
Serena
Carolina
C
Guarro
Josep
J
D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D016867:Immunocompromised Host; D008081:Liposomes; D018655:Lymphocyte Count; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008271:Mycetoma / Q000188:drug therapy*; D021681:Scedosporium
D000935:Antifungal Agents; D008081:Liposomes; C068538:liposomal amphotericin B; D016179:Granulocyte Colony-Stimulating Factor; D000666:Amphotericin B